Životopis

ŽIVOTOPIS

Jméno: Prof. MUDr. Eva Havrdová, CSc.

Datum narození: 14. 8. 1955, r.č. 555814/0093

Bydliště: Pecerady 196, 257 41 Týnec nad Sázavou

Vzdělání: 1975-1981 Fakulta všeobecného lékařství, Universita Karlova, Praha

1984 atestace prvního stupně v oboru neurologie

1992 atestace druhého stupně v oboru neurologie

1995 kandidátská disertační práce

2003 habilitace v oboru neurologie

2010 jmenování profesorem pro obor neurologie

Kurzy: Training Course on Myelination and Demyelination in the CNS (Varna 1982)

EEG - 1985

Novinky v neurochirurgii a neuroonkologii (1991)

Good clinical practice (SÚKL 1992)

Intenzivní péče v neurologii (1993)

Cytokiny (1993)

Training Course for GCP Inspectors and Country Counsellors on Clinical Trials (Drug Information Association, SÚKL 1994)

Training Course in Neuroimmunology, Haag 1996

Training Course in Headache, Rome 1996

Training Course in Intensive Care, Rome 1996

Training Course in Neuroimmunology, Toronto, 1999

Good clinical practice, 4.10.2011

Studijní pobyty:

Neuroimmunology Lab, Dpt. of Neurology, Indiana University Medical Center, Indianapolis, USA - březen 1994

Dpt. of Neuroimmunology, Queen Square, London, květen 1995

Center for Multiple Sclerosis and Neuroimmunopathological Disorders, Indianapolis, USA - červen 1999

Členství ve společnostech: Č.neurologická spol., člen výboru, člen výboru Sekce pro Neuroimunologii a likvorologii ČNS ČLS JEP, Č.spol. pro alergologii a klin. imunologii, Č. imunologická společnost, ECTRIMS (European Committee for Treatment and Research od Multiple Sclerosis) - člen výkonného výboru (2002-2006), EMSP (European Multiple Sclerosis Platform) – člen výkonného výboru 2006 -10

EBMT - člen evropské skupiny pro transplantace kostní dřeně u RS

WHO - spolupráce na vytváření Guidelines for diagnosis and treatment of remitting MS, Řím, Ženeva 1998-9
Pracoviště: Neurologická klinika IPVZ FTN, Vídeňská 800, Praha 4 (od r.1981 do 1996)

Katedra neurologie IPVZ, Ruská 85, Praha 10 (1991- 1997)

Neurol. klinika 1.LF UK, Kateřinská 30, Praha 2 (od 1996) - vedoucí Centra pro

demyelinizační onemocnění Neurol. kliniky 1.LF UK a VFN

Pedagogická činnost:

Přednášky na téma sclerosis multiplex, záněty CNS pro studenty 1.LF UK od 1996.

Přednášky o základech neuroimunologie, patogeneze a terapii sclerosis multiplex, patogeneze a léčbě Parkinsonovy nemoci, Huntingtonovy nemoci, tremoru a spasticity pro lékaře na školicím místě před atestací II. stupně v neurologii (IPVZ) a v postgraduálních kursech IPVZ pro posudkové lékaře a imunology.

Příprava a vedení kurzů IPVZ: "Problematika parkinsonismu" (X/1992, "Problematika demyelinizace I" (1993-7). organizace a vedení sympozia Sekce pro neuroimunologii a likvorologii ČNS ČLS JEP "Demyelinizace VIII-XV (1998-2012).

Vedení školicího místa IPVZ "Patogeneze a léčba roztroušené sklerózy mozkomíšní" (od 1993 -2000)

Postgraduální přednášky na neurofarmakologických sympoziích a neurologických kongresech (týkající se imunopatogeneze a léčby RS, neuroimunologie).

Školitel v oboru neurovědy od 2003

Vědeckovýzkumná činnost :

1. 
   roztroušená skleróza mozkomíšní - imunopatogeneza, léčba, komplikace léčby steroidy - osteoporóza, rehabilitace, symptomatická léčba, genetické a imunologické markery responzivity na léčbu, imunosuprese v léčbě RS
   
2. 
   extrapyramidové syndromy - Parkinsonova choroba a Huntingtonova choroba (do 1998)
   
3. 
   migrena – léčba (do 1998)
   

Řešení grantů: IGA MZ ČR: 1538-2, 1539-2, 2777-3, NF/6780-3, NF 6560-3, NM/31-3, 3146-3, GA UK 1.LF UK: C 2/2002, GA ČR 309/02/D066, NR 8188-3, IGA FH 8523-3, 1A8713-5/2005, IGA MZ NR/-8523-3

Výběr z publikací:

Havrdová E: Neuroimmunologie, Maxdorf, Praha, 2001 (cena Hlávkovy nadace a ČLF za nejlepší publikaci v oboru medicíny za rok 2001, cena ČNS ČLS JEP za nejlepší publikaci v oboru neurologie za rok 2001)

Havrdová E: Roztroušená skleróza mozkomíšní, Triton 1998, 2000, 2002
Havrdová E: Roztroušená skleróza mozkomíšní: Farmakoterapie, Maxdorf 2006, 2009
Fassas A, Passweg JR, Anagnostopoulos A,Kazis A, Kozak T, Havrdova E, Carreras E, Graus F, Kashyap A, Openshaw H, Schipperus M, Deconinck E, Mancardi G, Marmont A, Hansz J, Rabusin M, Zuazu Nagore FJ, Besalduch J, Dentamaro T, Fouillard L, Hertenstein B, La Nasa G, Musso M, Papineschi F, Rowe JM, Saccardi R, Steck A, Kappos L, Gratwohl A, Tyndall A for the Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation): Hematopoetic stem cell transplantation for multiple sclerosis: a retrospective study. J Neurol. 2002, vol 249, No 8, p. 1088-1097 3,345
Kozák T, Havrdová E, Piťha J, Gregora E, Pytlík R, Maaloufová J, Kobylka P, Vodvářková Š.: Immunoablative Therapy with Autologous Stem Cell Transplantation in the Treatment of Poor Risk Multiple Sclerosis. Transplantation Proceedings, 2001; 33/3: 2179-2181
Roth J., Židovská J., Růžičková Š., Havrdová E., Uhrová T., Preiss N., Línek V., Wolfová M., Růžička E., Jech R., Bauer J.: The relationship between clinical signs, the atrophy of caudate nucleus and CAG triplets repeat in Huntington´s Disease. J Neurol 1998;245:454
Kozák T, Havrdová E , Piťha J , Gregora E et al: High dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000, Mar;25(5):525-31
Kozák T, Havrdová E , Piťha J , Gregora E et al: High dose immunosuppression with hemopoietic stem cell support in the treatment of multiple sclerosis. IMAJ 2000, 8, 610-614
Sánchez D, Tučková L, Šebo P, Michalak M, Whelan A, Šterzl I, Jelínková L, Havrdová E, Imramovská M, Beneš Z, Krupičková S, Tlaskalová-Hogenová H: Occurence of IgA and IgG autoantibodies to calreticulin in coelic disease and various autoimmune diseases. J Autoimmunity 2000, 15, 441-9
Roth J, Havrdova E, Ruzicka E: Atrophy of caudate nucleus in Huntington´s disease measured by computed tomography. J Neurol 2000, 415:880-881
Kalistová, H, Havrdová, E, Uhrová, J, Zeman, D, Týblová, M, Mrázová, K. Myelin basic protein in multiple sclerosis and other neurological disorders. J Neurol 2003 250: 874-875
International Working Group for Treatment Optimization in MS. Treatment optimization in multiple sclerosis: report of an international consensus meeting. Eur J Neurol. 2004 Jan;11(1):43-7.
Horáková Dana, Havrdová Eva: Intravenosní imunoglobuliny v léčbě neuroimunitních onemocnění, Neurologie 2005, Triton, 27-35
Stepan JJ, Havrdova E, Tyblova M, Horakova D, Ticha V, Novakova I, Zikan V. Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. Clin Chim Acta. 2004 Oct;348(1-2):147-54. IF=1.633
Havrdová E., Týblová M., Štěpán J., Horáková D., Tichá V., Nováková I.,Zelená L., Zikán V., Hlásenská J. Výskyt osteoporózy u pacientů s roztroušenou sklerózou v závislosti na míře kortikoterapie a stupni hybného postižení Čes a slov Neurol Neurochir 67/100, 2004, No 4, 234-240
Havrdová E, Horáková D. Roztroušená skleróza. Postgraduální medicína 2004 (6) 4: 382-9
Bušek P., Horáková D., Opavský J., Salinger J., Jech R., Šlachta R., Havrdová E. :Krátkodobá spektrální analýza variability srdeční frekvence u roztroušené sklerozy, Čes a Slov Neurol a Neuroch, 67/100, 2004; No 1: 37-42
Piťha J, Havrdová E:  Axonální patologie u roztroušené sklerózy.  Čes a Slov Neurol a Neuroch 68/101, 2005; No 3, 154-158.
Rasova K, Brandejsky P, Havrdova E, Zalisova M, Rexova P Spiroergometric and spirometric parameters in patients with multiple sclerosis: are there any links between these parameters and fatigue, depression, neurological impairment, disability, handicap and quality of life in multiple sclerosis? Mult Scler. 2005 Apr;11(2):213-21. IF=2.849
Frohman EM, Stuve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol. 2005 Oct;62(10):1519-30. IF=4.835
Rasova K, Krasensky J, Havrdova E, Obenberger J, Seidel Z, Dolezal O, Rexova P, Zalisova M. Is it possible to actively and purposely make use of plasticity and adaptability in the neurorehabilitation treatment of multiple sclerosis patients? A pilot project. Clin Rehabil. 2005 Mar;19(2):170-81. IF=1.115
Havrdova E, Horakova D, Kovarova I, Krasulova E. [Future possibilities of the multiple sclerosis treatment] Cas Lek Cesk. 2005;144(10):663-5
Kalousova M, Havrdova E, Mrazova K, Spacek P, Braun M, Uhrova J, Germanova A, Zima T. Advanced glycoxidation end products in patients with multiple sclerosis. Prague Med Rep. 2005;106(2):167-74
Havrdová E: Význam časné léčby roztroušené sklerózy mozkomíšní. Neurologie pro praxi 2005, 4:291-4
Havrdova E. Aggressive multiple sclerosis-is there a role for stem cell transplantation? J Neurol. 2005 Sep;252 Suppl 3:iii34-iii37, IF=3.140

Karussis D, Biermann LD, Bohlega S, Boiko A, Chofflon M, Fazekas F, Freedman M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Miller A; the International Working Group for Treatment Optimization in MS.A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol. 2006 Jan;13(1):61-71. 2,225

Frohman EM, Havrdova E, Levinson B, Slanar O. Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms.Mult Scler. 2006 Feb;12(1):108-11. 2,849

Polman CH, O´Connor P, Havrdová E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. NEJM, vol.354, No 9, March 2006, 899-910 38,570

Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol. 2006 Apr;63(4):614-9. 4,835

Rasova K, Havrdova E, Brandejsky P, Zalisova M, Foubikova B, Martinkova P. Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spiroergometric parameters in patients with multiple sclerosis. Mult Scler. 2006 Apr;12(2):227-34. 2,849

Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E, Carreras E, Saiz A, Lowenberg B, te Boekhorst PA, Gualandio F, Openshaw H, Longo G, Pagliai F, Massacesi L, Deconink E, Ouyang J, Nagore FJ, Besalduch J, Lisukov IA, Bonini A, Merelli E, Slavino S, Gratwohl A, Passweg J, Tyndall A, Steck AJ, Andolina M, Capobianco M, Martin JL, Lugaresi A, Meucci G, Saez RA, Clark RE, Fernandez MN, Fouillard L, Herstenstein B, Koza V, Cocco E, Baurmann H, Mancardi GL; Autoimmune Diseases Working Party of EBMT. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler. 2006 Dec;12(6):814-23. 2,849

Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007 Apr 24;68(17):1390-401 5,690
Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007 Apr 17;68(16):1299-304 5,690
Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, Ravnborg M, Hauser SL, Rudick RA, Weiner HL, O'Connor PW, King J, Radue EW, Yousry T, Major EO, Clifford DB. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.
Lancet Neurol. 2007 May;6(5):431-41. 9,479
Phillips JT, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Polman CH, Lublin FD, Giovannoni G, Wajgt A, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology. 2006 Nov 14;67(9):1717-8. No abstract available. Erratum in: Neurology. 2007 Feb 6;68(6):473. 5,690
Goodin DS, Biermann LD, Bohlega S, Boiko A, Chofflon M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Karussis D, Miller A, Pakdaman H, Selmaj K, Sharief M; International Working Group for Treatment Optimization in MS. Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Curr Med Res Opin. 2007 Nov;23(11):2823-32. 3,062
Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS. Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. J Neurol. 2007 Jul;254(7):827-37. 2,984
Mareckova H, Havrdova E, Krasulova E, Vankova Z, Koberová M, Sterzl I. Natalizumab in the treatment of patients with multiple sclerosis: first experience. Ann N Y Acad Sci. 2007 Sep;1110:465-73 1,930
Horakova D, Cox JL, Havrdova E, Hussein S, Dolezal O, Cookfair D, Dwyer MG, Seidl Z, Bergsland N, Vaneckova M, Zivadinov R. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years. A case control study. J Neurol Neurosurg Psychiatry. 2007 Jun 5; [Epub ahead of print 3,63
Dolezal O, Dwyer MG, Horakova D, Havrdova E, Minagar A, Balachandran S, Bergsland N, Seidl Z, Vaneckova M, Fritz D, Krasensky J, Zivadinov R. Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis. Int Rev Neurobiol. 2007;79:475-89. 1,724
Gold R, Jawad A, Miller DH, Henderson DC, Fassas A, Fierz W, Hartung HP. Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol. 2007 Jul;187(1-2):156-8. Epub 2007 May 11.

Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007 Oct 2;69(14):1391-403. Epub 2007 Aug 29. 5,690

Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007 Oct;62(4):335-46. 8,051

Páv M, Kovářů H, Fišerová A, Havrdová E, Lisá V. Neurobiological aspects of depressive disorder and antidepressant treatment: role of glia. Physiol Res. 2008;57(2):151-64. Epub 2007 May 16 2,093

Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5062 Study Group. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008 Jun 21;371(9630):2085-92. IF= 30.758

Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, limmroth V et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372:1463-72 IF= 30.758

Masek M, Vaneckova M, Krasensky J, Danes J, Havrdova E, Hrebikova T, Seidl Z.Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status. Neuro Endocrinol Lett. 2008 Aug;29(4):461-6. IF=1,047

Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L; BHT-3009 Study Group.Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol. 2008 May;63(5):611-20. IF=8.717
Horakova D, Cox JL, Havrdova E, Hussein S, Dolezal O, Cookfair D, Dwyer MG, Seidl Z, Bergsland N, Vaneckova M, Zivadinov R. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):407-14. Epub 2007 Jun 5. IF=3,632.
Havrdová E. Roztroušená skleróza. Č a Slov Neurol Neurochir 2008;71/104, (2): 121-132 IF= 0.319
Krasulová E, Havrdová E. Léčba relaps-remitentní roztroušené sklerózy. Neurol.pro praxi 2008, 9(4):218-222
Krasulová E, Havrdová E. Současná léčba relaps-remitentní roztroušené sklerózy a perspektivy do budoucna. Klinická farmakologie a farmacie 2008 (22), 1:23-29
Vaneckova M, Seidl Z, Krasensky J, Havrdova E, Horakova D, Dolezal O, Burgetova A, Masek M. Patients' stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosis. Eur Neurol. 2009;61(5):278-84. IF=1.494
Horáková D, Dwyer M, Havrdová E, Cox JL, Doležal O, Bergsland N, Rimes B, Seidl Z, Vaněčková M, Zivadinov R. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis. A 5-year longitudinal study. J Neurol Sci. 2009 Jul 15;282(1-2):112-9. Epub 2009 Jan 24.
Havrdova E, Zivadinov R, Krasensky J, Dwyer M, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox J, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler. 2009 Aug;15(8):965-76. Epub 2009 May 22.
Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R.Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 Mar;8(3):254-60. IF=18,126
Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.J Neurol. 2009 Mar;256(3):405-15. Epub 2009 Mar 18

De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC, Aubin C, Bauer D, Heubach JF, Sandbrink R, Tyblova M, Lelkova P; Steering committee of the BENEFIT study; Steering committee of the BEYOND study; Steering committee of the LTF study; Steering committee of the CCR1 study, Havrdova E, Pohl C, Horakova D, Ascherio A, Hafler DA, Karlson EW. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol. 2009 Dec;8(12):1111-9. Epub 2009 Oct 29. IF=18,126

Havrdová E. Možnosti farmakologické léčby kliniky izolovaného syndromu. Farmakoterapie 2009;5(6);629-635.
Krasulová E, Trneny M, Kozák T, Vacková B, Pohlreich D, Kemlink D, Kobylka P, Kovárová I, Lhotáková P, Havrdová E. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler. 2010 Jun;16(6):685-93. IF=3.279

Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology. 2010 Apr 27;74 Suppl 3:S3-7. IF= 8.172

Burt RK, Abinun M, Farge-Bancel D, Fassas A, Hiepe F, Havrdová E, Ikehara S, Loh Y, Marmont du Haut Champ A, Voltarelli JC, Snowden J, Slavin S. Risks of immune system treatments. Science. 2010 May 14;328(5980):825-6. IF= 29.747

Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5063 Study Group. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler. 2010 Nov;16(11):1360-6. IF=3.279

MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, O'Neill GN, Dawson K. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol. 2011 Mar;258(3):449-56. IF= 2.903
Horáková D, Kýr M, Havrdová E, Doležal O, Lelková P, Pospíšilová L, Bergsland N, Dwyer MG, Cox JL, Hussein S, Seidl Z, Vaněčková M, Krásenský J, Zivadinov R. Apolipoprotein E ε4-Positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: a 15-year disease history model based on a 4-year longitudinal study. Folia Biol (Praha). 2010;56(6):242-51. IF= 0.924

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. IF= 9.317

Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Tamaño-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Ramanathan M. HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. J Neuroimmunol. 2011 Jul;236(1-2):76-80. IF= 2.841

Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW, Sørensen PS, King J. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011 Aug;10(8):745-58. Review.

Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, Dawson K, O'Neill GN. Effect of BG-12 on contrast-enhancing lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler. 2011 Aug 30. [Epub ahead of print]

Blahova Dusankova J, Kalincik T, Dolezal T, Kobelt G, Havrdova E. Cost of multiple sclerosis in the Czech Republic: The COMS Study. Mult Scler. 2011 Sep 30. [Epub ahead of print]

Havrdová E. Fingolimod. Remedia 2011; 21: 297-303.

Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol. 2011 Oct 19. [Epub ahead of print]

Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012 Feb;18(2):143-52.

Kalincik T, Horakova D, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Clin Neurol Neurosurg. 2012 Mar 6. [Epub ahead of print]

Horakova D, Kalincik T, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E.

Early predictors of non-response to interferon in multiple sclerosis. Acta Neurol Scand. 2012 Mar 16.

Bergsland N, Horakova D, Dwyer MG, Dolezal O, Seidl ZK, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis. AJNR Am J Neuroradiol. 2012 Apr 12. [Epub ahead of print]

Zborníková P, Králík L, Lelková P, Kalinčík T, Havrdová E, Martásek P. Microsatellite polymorphism in haem oxygenase 1 gene promoter in multiple sclerosis. Folia Biol (Praha). 2012;58(2):69-74.

Zikán V, Týblová M, Raška I Jr, Havrdová E, Luchavová M, Michalská D, Kuběna AA.

Bone mineral density and body composition in men with multiple sclerosis chronically treated with low-dose glucocorticoids. Physiol Res. 2012 Jun 6. [Epub ahead of print]
Vávrová J, Kemlink D, Sonka K, Havrdová E, Horáková D, Pardini B, Müller-Myhsok B, Winkelmann J. Restless legs syndrome in Czech patients with multiple sclerosis: An epidemiological and genetic study. Sleep Med. 2012 Aug;13(7):848-51. Epub 2012 May 19.
Vaneckova M, Kalincik T, Krasensky J, Horakova D, Havrdova E, Hrebikova T, Seidl Z. Corpus Callosum Atrophy - A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study. Eur Neurol. 2012 Jun 6;68(1):23-27. [Epub ahead of print]
Meyniel C, Spelman T, Jokubaitis VG, Trojano M, Izquierdo G, Grand'maison F, Oreja-Guevara C, Boz C, Lugaresi A, Girard M, Grammond P, Iuliano G, Fiol M, Cabrera-Gomez JA, Fernandez-Bolanos R, Giuliani G, Lechner-Scott J, Cristiano E, Herbert J, Petkovska-Boskova T, Bergamaschi R, van Pesch V, Moore F, Vella N, Slee M, Santiago V, Barnett M, Havrdova E, Young C, Sirbu CA, Tanner M, Rutherford M, Butzkueven H; on behalf of the MSBasis Study Group. Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS One. 2012;7(6):e38661. Epub 2012 Jun 29.
Kalincik T, Vaneckova M, Tyblova M, Krasensky J, Seidl Z, et al. (2012) Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study. PLoS ONE 7(11): e50101. doi:10.1371/journal.pone.0050101